Nixon Peabody Trust’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.08M Buy
8,249
+147
+2% +$31.6K 0.15% 77
2026
Q1
$1.76M Sell
8,102
-207
-2% -$45.9K 0.14% 76
2025
Q4
$1.9M Buy
8,309
+1,290
+18% +$294K 0.14% 77
2025
Q3
$1.63M Buy
7,019
+194
+3% +$39.5K 0.12% 81
2025
Q2
$1.27M Buy
6,825
+2
+0% +$372 0.1% 85
2025
Q1
$1.43M Buy
6,823
+331
+5% +$64.3K 0.12% 76
2024
Q4
$1.15M Sell
6,492
-330
-5% -$60.7K 0.1% 75
2024
Q3
$1.35M Hold
6,822
0.11% 68
2024
Q2
$1.17M Hold
6,822
0.1% 68
2024
Q1
$1.24M Sell
6,822
-308
-4% -$53.1K 0.11% 62
2023
Q4
$1.1M Buy
+7,130
New +$1.04M 0.12% 62
2022
Q2
Sell
-1,863
Closed -$302K 70
2022
Q1
$302K Sell
1,863
-1,200
-39% -$174K 0.1% 67
2021
Q4
$415K Sell
3,063
-1,607
-34% -$190K 0.13% 67
2021
Q3
$504K Buy
+4,670
New +$534K 0.18% 61

Other funds holding ABBV

Nixon Peabody Trust's ABBV Position: Q2 2026 in Review

Nixon Peabody Trust increased its AbbVie (ABBV) stake by 1.8% in Q2 2026, buying an estimated $31.6K and bringing the position to 8,249 shares worth $2.08M. The position accounts for 0.15% of the portfolio, ranked #77.

Nixon Peabody Trust first reported a position in ABBV in Q3 2021 and has held it in 14 quarters since. 1,743 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Nixon Peabody Trust held 8,249 shares of AbbVie worth $2.08M as of Q2 2026.
  • Nixon Peabody Trust bought 147 AbbVie shares in Q2 2026, an estimated $31.6K.
  • AbbVie made up 0.15% of Nixon Peabody Trust's portfolio in Q2 2026, its #77 holding.
  • Nixon Peabody Trust first reported a position in AbbVie in Q3 2021 and has held it in 14 quarters since.
  • 1,743 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Nixon Peabody Trust's 13F filing for Q2 2026, filed 27 Jul 2026.